GLP-1 Medicines in Type 2 Diabetes: What a New Consensus Supports—and What They Do Not Replace
GLP-1 receptor agonists are often discussed as if they are a single answer to a very complicated condition. In reality, they are one category of prescription medicines that may help selected people with type 2 diabetes, obesity, chronic kidney disease, or cardiovascular risk. The decision to use one depends on the person’s medical history, treatment […]
Tirzepatide and Cardiovascular Risk: What New Evidence—and the Updated Mounjaro Label—Mean for Type 2 Diabetes Care
Tirzepatide, sold as Mounjaro for type 2 diabetes in the United States, has become a major part of the public conversation about diabetes and metabolic health. Recent reporting has focused on two related developments: a large real-world study linking tirzepatide with fewer major cardiovascular events than a cardiovascular-neutral comparison medicine, and a new Mounjaro indication […]
Type 2 Diabetes and Brain Health: What Recent Studies on Blood Sugar and Medications Can—and Cannot—Tell Us
Type 2 diabetes is often discussed through blood glucose, weight, A1c, blood pressure, or cholesterol. Those measures matter. But people living with diabetes are also asking a broader question: What does metabolic health mean for the brain over time? Brain health belongs in the type 2 diabetes conversation That question has become more urgent as […]
Digital Diabetes Care Is Expanding Around GLP-1s. The Real Test Is Whether Support Extends Beyond the Prescription.
GLP-1 medicines are changing more than medication lists. They are changing the market for diabetes support. Employers, health plans, clinicians, and patients are all asking versions of the same question: if a person starts a GLP-1 medicine, what happens around the prescription? Who helps them understand side effects, protect nutrition, stay active, navigate coverage, monitor […]
A GLP-1 Prescription Is Not a Complete Care Plan: What Responsible Evaluation and Follow-Up Look Like
GLP-1 medicines have become a major part of conversations about weight, blood sugar, and metabolic health. That visibility has created opportunity: some people who once felt shut out of care are now asking better questions about diabetes, obesity, and long-term risk. It has also created a problem. A medication can be presented online as if […]
Semaglutide and Fatty Liver Disease: What the MASH Evidence Actually Shows
Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of fatty liver disease in which excess fat in the liver is accompanied by inflammation and liver-cell injury. Over time, some people develop fibrosis, or scarring, which can progress to cirrhosis and other serious complications. Why MASH matters in a type 2 diabetes conversation MASH is closely […]
GLP-1s After 60: Why Medication Decisions Must Protect Strength, Function, and Independence
Source note: This article was prompted by reporting on GLP-1 medicines and aging, plus a commentary on the history of weight-loss culture. The question is not simply “Will it cause weight loss?” GLP-1 receptor agonists have changed the conversation around obesity and type 2 diabetes. These medicines can improve glucose control in people with type […]
Novo’s Next GLP-1 Just Hit 89% A1c Target
Novo Nordisk’s next-generation triple-agonist zenagamtide just hit 89.1% A1c target attainment in phase 2 — one of the highest rates ever reported for a Type 2 diabetes therapy, per the ADA 2026 Scientific Sessions coverage and the Novo Nordisk pipeline announcement. In adults with Type 2 diabetes, the highest dose produced 14.6% body-weight loss and […]
An Oral GLP-1 Just Hit 89% A1c Target
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week […]
Generic Dapagliflozin Just Got Approved.
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower […]